Novavax (NVAX) Reiterated at Overweight by Cantor Fitzgerald: Nuvaxovid Sales Good
Tweet Send to a Friend
Cantor Fitzgerald analyst Pete Stavropoulos reiterated an Overweight rating and $18.00 price target on Novavax (NASDAQ: NVAX).The analyst commented, "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
